Tel Aviv-based genetic testing company Identifai-Genetics has raised USD 3.3 million in a post-seed funding round led by eHealth Ventures and included participation from Dr. Ron Sabar, founder and CMO of Sabar Health, among others. The company claims to have raised over USD 6 million in equity investments and R&D grants. The planned uses of the funds were not disclosed.

Identifai Genetics is focused on developing a liquid biopsy test that uses maternal blood samples for the non-invasive detection of fetal genetic disorders at an early stage of pregnancy. The company claims to offer the only available clinical solution for an early, non-invasive prenatal genetic screening, from point mutations to chromosomal anomalies. By identifying severe genetic disorders with high accuracy, Identifai-Genetics aims to help mitigate the risk of amniocentesis and placental cysts. The company is planning to launch clinical studies to further validate its technology.